Trials / Not Yet Recruiting
Not Yet RecruitingNCT07148427
Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma
A Single-arm, Phase II Clinical Study Protocol of Lparomlimab and Tuvonralimab in Combination With Regorafenib and Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A single-arm, Phase II clinical study protocol of Apatolimab Tovolimab in combination with regorafenib and chemotherapy as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iparomlimab and Tuvonralimab combination with regorafenib and chemotherapy | Iparomlimab and Tuvonralimab：5mg/kg，Intravenous infusion，Q3W regorafenib：80mg，oral administration once daily from Day 1 to Day 14 chemotherapy：XELOX or SOX |
Timeline
- Start date
- 2025-09-20
- Primary completion
- 2027-12-30
- Completion
- 2028-09-01
- First posted
- 2025-08-29
- Last updated
- 2025-08-29
Source: ClinicalTrials.gov record NCT07148427. Inclusion in this directory is not an endorsement.